Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 100 participants.
Also called NCT05350592
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Registry
-
NCT05350592 -
2021-002028-19 -
U1111-1277-8523
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05350592. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-13 (actual); primary completion 2025-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock
- Acronym
- DOBERMANN
- Condition
- Acute Myocardial Infarction
- Condition
- Cardiogenic Shock
- Intervention (Drug)
- Tocilizumab
- Intervention (Drug)
- Dobutamine
- Intervention (Drug)
- NaCl 0.9%
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Collaborator
- Novo Nordisk A/S
- Collaborator
- Simon Spies Fonden
- Collaborator
- Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat
Record details
- Record id
cardio:ct-nct05350592- Content hash
a18f5aa94e68d91fe1324179989f9ea77d33c105a9d48e83988f3e22d0f569ce